EP1877394A1 - Verfahren zur herstellung von escitalopram oder seinen säureadditionssalzen - Google Patents

Verfahren zur herstellung von escitalopram oder seinen säureadditionssalzen

Info

Publication number
EP1877394A1
EP1877394A1 EP06728421A EP06728421A EP1877394A1 EP 1877394 A1 EP1877394 A1 EP 1877394A1 EP 06728421 A EP06728421 A EP 06728421A EP 06728421 A EP06728421 A EP 06728421A EP 1877394 A1 EP1877394 A1 EP 1877394A1
Authority
EP
European Patent Office
Prior art keywords
escitalopram
acid
mixture
base
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06728421A
Other languages
English (en)
French (fr)
Inventor
Prasenjit Prafulla Das
Santosh Laxman Goankar
Sulur G. Manjunatha
Ambati Narahari Babu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jubilant Organosys Ltd
Original Assignee
Jubilant Organosys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Organosys Ltd filed Critical Jubilant Organosys Ltd
Publication of EP1877394A1 publication Critical patent/EP1877394A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Definitions

  • Escitalopram which is the S-enantiomer of well known antidepressant drug Citalopram, /. e. (S)- 1 -[3 -(dimethylamino)propyl] - 1 -(4-flouorphenyl)- 1 ,3 -dihydro-5 - isobenzofuran carbonitrile or a pharmaceutically acceptable salt thereof.
  • Citalopram is a well-known antidepressant drug that has now been in the market for some years and has the following structure shown in figure 1 :
  • Figure 1 It is a selective centrally acting serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, accordingly having antidepressant activities.
  • Citalopram was first disclosed in DE 2,657,013, corresponding to US 4,136,193. This patent publication outlines a process for preparation of Citalopram from the corresponding 5-bromo derivatives by reaction with cuprous cyanide in a suitable solvent.
  • US' 193 describes the C-alkylation reaction of 5-cyanophthalane with 3-NjN'-dimethylaminopropyl chloride using sodium hydride as a base ⁇ n dimethyl sulphoxide (DMSO) medium. 13 volumes of DMSO is used in this reaction with respect to 5-cyanophthalane.
  • DMSO dimethyl sulphoxide
  • Citalopram base is isolated as oil, which is purified by high vacuum distillation (0.03mm at 175-18O 0 C) and then converted into acid addition salts by conventional methods.
  • a main drawback of this process is the need to purify the oily Citalopram base using high vacuum distillation (0.03mm) at 175-18O 0 C. Achieving such a high vacuum at plant level is difficult and apart from these constraints, the process has another drawback in that Citalopram base having a cyano group at the 5 th position of the bicyclic ring system may decompose during high vacuum distillation at high temperature to form Citalopram carboxamide as one of the impurity, resulting in poor quality product and yield.
  • US Patent No.4,650,884 discloses diol of formula (II), 4-[4-(dimethylamino)-l- (4 ' -fluorophenyl)- 1 -hydroxy- 1 -butyl] -3 -(3 -hydroxy methyl)-benzonitrile, its preparation and use as an intermediate in the preparation of Citalopram. Further processes for the preparation of Citalopram by exchange of 5-halogen or CF 3 -(CF 2 ) n - SO 2 -O-, n being 0-8, with cyano are disclosed in WOOOl 1926 and WO0013648.
  • Escitalopram the pharmaceutical activity thereof and crystalline oxalate are disclosed in US Patent no. 4,943,590.
  • Methods for the preparation of Escitalopram along with the disclosure of Escitalopram free base existing as an oil as well as the oxalic, pamoic and L-(+)-tartaric acid addition salts of Escitalopram are disclosed in US'590.
  • the diol is separated into enantiomers by stereo selective crystallization with an enantiomerically pure acid such as (+)-di- J p- toluoyltartaric acid, whereupon the S-enantiomer of the diol is enantioselectively converted to Escitalopram.
  • an enantiomerically pure acid such as (+)-di- J p- toluoyltartaric acid
  • WO 03/087081 discloses the process in which the racemic diol intermediate is treated with optically active acid such as (+)-di-/?-toluoyl tartaric acid to form a diastereiomeric salt. It is subjected to enantiomeric selective cyclization to get 5- substituted Escitalopram, which is replacement of bromine by a nitrile group to get pure optically active acid such as (+)-di-/?-toluoyl tartaric acid to form a diastereiomeric salt. It is subjected to enantiomeric selective cyclization to get 5- substituted Escitalopram, which is replacement of bromine by a nitrile group to get pure
  • the present invention provides a process for the preparation of highly pure Escitalopram or its acid addition salts thereof, which comprises: a) reacting racemic diol or its ester derivative (III) with an optically active acid and at least one solvent to get enantiomerically pure diastereomer (IHA); b) separating the enantiomerically pure diastereomer (IIIA) from its optically active acid salt by treating it with base and followed by stereo selective cyclization; c) separating the Escitalopram base;
  • said optically active acid is selected from the group consisting of tartaric acid, diberizoyl tartaric acid, di-j9-toluoyl tartaric acid, bis-napthyl phosphoric acid, and 10-camphor sulphonic acid.
  • said solvent is selected from the group consisting of lower alcohol having 1 to 4 carbon atoms such as methanol, ethanol, isopropyl alcohol and butyl alcohol; acetonitrile; acetone or any mixture thereof.
  • said base is selected from the group consisting of triethyl amine, alkali metal carbonates, bicarbonates and their hydroxides and liquid ammonia.
  • said stereo selective cyclization is carried out by reacting with methane sulphonyl chloride or p-toluene sulphonyl chloride in presence of a base.
  • a base is triethyl amine.
  • said enantiomerically pure diastereomer (IIIA) is optionally purified in a solvent or a mixture of solvents.
  • said solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, ethyl acetate and acetone or mixture thereof.
  • said Escitalopram or its acid addition salt is purified using a mixture of solvents.
  • said mixture of solvents contains at least isopropyl alcohol and one or more of methanol, ethanol, ethyl acetate, acetone or mixtures thereof.
  • said highly pure Escitalopram is optionally converted into its acid addition salt.
  • the Escitalopram or its acid addition salts of the present invention have a chiral purity of 99.5% or greater and HPLC purity of 99.5% or greater.
  • the Escitalopram or its acid addition salts of the present invention have a a chiral purity of 99.5% or greater and HPLC purity of 99% or greater.
  • the Escitalopram or its acid addition salts of the present invention have a a chiral purity of 99% or greater.
  • the disclosed embodiment of the present invention deals with a process for the preparation of highly pure Escitalopram or its acid addition salts thereof of formula (I) according to scheme 4;
  • racemic diol or its ester derivative (III) which comprises: a) reacting racemic diol or its ester derivative (III) with an optically active acid and at least one solvent to get enantiomerically pure diastereomer (IIIA); b) separating the enantiomerically pure diastereomer from its optically active acid salt by treating it with base and followed by stereo selective cyclization; c) separating the Escitalopram base; d) optionally, converting Escitalopram base into its acid addition salt.
  • racemic diol compound of formula III is treated with pure optically active acid in a mixture of solvents to get an enantiomerically pure diol of formula IIIA.
  • the optically active acid used herein is selected from the group consisting of but not limited to tartaric acid, dibenzoyl tartaric acid, di-p-toluoyl tartaric acid, bis-napthyl phosphoric acid, and 10-camphor sulphonic acid preferably di-j ⁇ ?-toluoyl tartatic acid.
  • the reaction is carried out in a solvent selected from the group consisting of lower alcohol having 1 to 4 carbon atoms such as methanol, ethanol, isopropyl alcohol and butyl alcohol; acetonitrile; acetone or mixture thereof preferably in a mixture of methanol and isopropyl alcohol.
  • the reaction is carried out firstly at a temperature of 40-60 0 C and then at a temperature of 20-25 0 C for a period of 6-24 hrs.
  • the reaction mixture is then cooled to 0-5 0 C to get the solid material, which is separated by filtration to get a compound of formula IIIA with a chiral purity of greater than 99%.
  • the compound of formula IIIA is optionally purified using a mixture of solvents to get the chiral purity in the range of 99.5-99.8%.
  • the solvent used herein is selected from the group consisting of but not limited to methanol, ethanol, isopropyl alcohol, ethyl acetate and acetone or mixture thereof preferably methanol and isopropyl alcohol or methanol and ethanol.
  • the purification is carried out by dissolving the compound of formula IIIA in a mixture of solvent at a temperature of 40-60 0 C and then cooled to 0- 5 0 C. Solid material is filtered to get the compound of formula IIIA with a chiral purity in the range of 99.5-99.8%.
  • the compound of formula IIIA is treated with base to get converted into a free diol (chirally pure), which is then subjected to stereo selective cyclization to get a compound of formula 11 i.e. Escilalopram base in chirally pure form with chiral purity greater than 99%.
  • the enantiomerically pure optically active acid salt of diol is then converted to optically pure diol by treating with a base in presence of water or optionally in a mixture of water and water immiscible solvent.
  • the base used herein is selected from the group consisting of organic and inorganic base.
  • Organic base are selected from the group of triethyl amine whereas inorganic base are selected from the group of alkali metal carbonates, bicarbonates and their hydroxides and liquid ammonia.
  • the reaction is carried out at a basic pH range of 7.0-9.0 preferably 8.0-8.5 and at a temperature range of O 0 C to room temperature.
  • the resulting solution is then extracted with water immiscible organic solvents to get the optically pure diol compound.
  • the solvent used herein is selected from the group consisting of toluene, chloroform, dichloromethane and dichloroethane preferably dichloromethane.
  • Optically pure diol as such i.e. without isolation is further subjected to stereo selective cyclization by reacting with a methane sulphonyl chloride or p-toluene sulphonyl chloride in presence of triethyl amine and a solvent system i.e. dichloromethane. After completion of the reaction, liquor ammonia is added to the reaction mass and separated the layers. The organic layer is washed with water and extracted with 10-20% aqueous acid.
  • the aqueous acid group is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid and acetic acid preferably acetic acid.
  • the aqueous extract is then diluted with water miscible organic solvent.
  • the solvent used herein is selected from the group consisting of methanol, ethanol, isopropyl alcohol, n-propanol, acetonitrile, tetrahydrofuran, dimethylformamide, dimethylacetamide, and dimethylsulfoxide preferably isopropyl alcohol.
  • the pH of the resulting solution is adjusted to basic by employing base selected from sodium, potassium hydroxide, and ammonia solution.
  • the preferred base employed to precipitate the Escitalopram base is liquid ammonia.
  • the reaction mass is cooled to 0-5 0 C and the solid is separated by filtration to get crystalline Escitalopram base with a chiral purity in the range of 99.5-99.8%.
  • the crystalline Escitalopram base is then converted to its acid addition salts by reacting it with acid in presence of solvent.
  • the solvent used herein is selected from the group consisting of methanol, ethanol, isopropanol, ethyl acetate, acetonitrile, tetrahydrofuran or mixtures thereof preferably isopropyl alcohol.
  • the amount of acid used herein is 1.0 equivalent to the Escitalopram base.
  • the acid used herein is selected from the group consisting of oxalic acid, hydrochloric acid, and hydrobromic acid, preferably oxalic acid.
  • the reaction mixture is stirred for 2-10 hours at 20-25 0 C.
  • the separated acid addition salts are filtered and washed with solvent to get pure Escitalopram acid addition salts.
  • the Escitalopram acid addition salt is further purified by employing simple purification in a solvent.
  • the solvent used herein for purification is selected from the group consisting of methanol, ethanol, isopropyl alcohol, ethyl acetate, acetone or mixtures thereof preferably mixture of methanol and ethyl acetate or methanol and isopropyl alcohol.
  • the racemic diol of formula III is prepared according to the process already disclosed in prior art i.e. in WO2005077927. In conclusion, this is an improved, economical and a high yielding process for the industrial production of highly pure Escitalopram base as well as Escitalopram acid addition salts using novel solvent system.
  • Example 1 illustrate specific embodiments of the present invention. They are, however, not intended to limit the scope of present invention in any way.
  • Example 1
  • the crystalline Escitalopram base (21 g) was dissolved in isopropyl alcohol (105mL) at 50-60 0 C.
  • Oxalic acid dihydrate (8.2 g) was added and the mixture was stirred at 50-60 0 C, cooled to 0-5°C, the solid formed was filtered and dried to get
  • the crystalline Escitalopram base (21 g) was dissolved in methanol (105mL) at
  • Oxalic acid dihydrate (8.2 g) was added and the mixture was stirred at 50-
  • Oxalic acid dihydrate (8.2 g) was added and the mixture was stirred at 50-

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP06728421A 2005-04-04 2006-04-04 Verfahren zur herstellung von escitalopram oder seinen säureadditionssalzen Withdrawn EP1877394A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN856DE2005 2005-04-04
PCT/IN2006/000124 WO2006106531A1 (en) 2005-04-04 2006-04-04 Process for the preparation of escitalopram or its acid addition salts

Publications (1)

Publication Number Publication Date
EP1877394A1 true EP1877394A1 (de) 2008-01-16

Family

ID=36694986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06728421A Withdrawn EP1877394A1 (de) 2005-04-04 2006-04-04 Verfahren zur herstellung von escitalopram oder seinen säureadditionssalzen

Country Status (2)

Country Link
EP (1) EP1877394A1 (de)
WO (1) WO2006106531A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2017271A1 (de) * 2007-07-06 2009-01-21 Aurobindo Pharma Limited Verfahren zur Herstellung von Escitalopram
US8022232B2 (en) 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
NZ570884A (en) * 2007-09-11 2010-03-26 Lundbeck & Co As H Fractionally crystallising 4-[4-(dimethyl amino)-1-(4'-fluorophenyl)-1-hydroxybutyI]-3-(hydroxymethyl)-benzonitrile and manufacturing escitalopram therefrom
CN102190600B (zh) * 2010-03-13 2015-04-15 浙江华海药业股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
ITMI20120105A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Soluzione acquosa di escitalopram ossalato e relativo utilizzo
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
CN103342664B (zh) * 2013-07-18 2014-11-05 山东新华制药股份有限公司 酒石酸盐的制备方法
CN104119248A (zh) * 2014-08-08 2014-10-29 广东东阳光药业有限公司 S-西酞普兰的制备方法
WO2016074225A1 (zh) * 2014-11-14 2016-05-19 浙江华海药业股份有限公司 一种拆分西酞普兰中间体5-氰二醇的方法
ES2827454T3 (es) * 2015-06-09 2021-05-21 Zhejiang Huahai Pharm Co Ltd Método para preparar un compuesto intermedio de citalopram diol
CN106324141B (zh) * 2016-08-30 2019-06-25 山东京卫制药有限公司 一种草酸艾司西酞普兰有关物质的高效液相检测方法
CN106892837A (zh) * 2017-03-23 2017-06-27 浙江师范大学 4‑[4‑(二甲氨基)‑1‑(4‑氟苯基)‑1‑羟丁基]‑3‑羟甲基苯腈的合成
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
CN110873762A (zh) * 2018-09-03 2020-03-10 万全万特制药江苏有限公司 Hplc法测定西酞普兰中间体及其有关物质的方法
KR102134179B1 (ko) * 2018-09-17 2020-07-16 (주)유케이케미팜 카보네이트를 이용한 시탈로프람 및 에스시탈로프람의 새로운 제조 방법
CN110590602B (zh) * 2019-09-25 2022-04-05 浙江海森药业股份有限公司 外消旋西酞普兰二醇的拆分精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
CA2381341A1 (en) 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
AU2003242990A1 (en) * 2003-01-17 2004-08-13 Pulla Reddy Muddasani Processes for the preparation of escitalopram and its precursor
CA2559703A1 (en) 2004-02-16 2005-08-25 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
KR101166280B1 (ko) * 2004-08-23 2013-11-27 썬 파마 글로벌 에프제트이 시탈로프램 및 에난티오머의 제조 방법
WO2006025071A1 (en) * 2004-09-02 2006-03-09 Natco Pharma Limited A process for the preparation of escitalopram

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006106531A1 *

Also Published As

Publication number Publication date
WO2006106531A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2006106531A1 (en) Process for the preparation of escitalopram or its acid addition salts
KR100439329B1 (ko) 순수한 시탈로프람의 제조방법
CA2450890C (en) Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram
JP2014514292A (ja) アミン中間体化合物を使用してドロネダロンを製造するための還元アミノ化方法
NO328542B1 (no) Fremgangsmate og forbindelse for fremstillingen av Citalopram
JP2014514291A (ja) メシル化によるドロネダロンの製造方法
JP2014509640A (ja) Ｎ−ブチル化によるドロネダロンの調製方法
JP4505335B2 (ja) ラセミ体シタロプラムジオール（ｒａｃｅｍｉｃｃｉｔａｌｏｐｒａｍｄｉｏｌ）および／またはＳ−もしくはＲ−シタロプラムジオールの製造方法、およびラセミ体シタロプラム、Ｒ−シタロプラムおよび／またはＳ−シタロプラムを製造するために、上記ジオールを使用する方法。
KR20100108400A (ko) 프로파길화된 아미노인단 유도체의 합성방법
CN117447387A (zh) 一种利特昔替尼关键中间体的制备方法
TW200831478A (en) Chromane derivatives, synthesis thereof, and intermediates thereto
US7939680B2 (en) Process for the preparation of Escitalopram
CN101265215B (zh) 一种右旋西酞普兰中间体s-型二醇的制备方法
CN102190600B (zh) 一种右旋西酞普兰中间体s-型二醇的制备方法
US20060009515A1 (en) Process and intermediates for preparing escitalopram
EP1700851B1 (de) Kristallines alkalisches citalopramdiol-zwischenprodukt
JP2010527345A (ja) エスシタロプラムの調製方法
US7148364B2 (en) Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
EP2017271A1 (de) Verfahren zur Herstellung von Escitalopram
KR101842425B1 (ko) 시탈로프람 및 에스시탈로프람의 신규 제조방법
HU207516B (en) Process for resolving cys-3-amino-4-/2-/2-furyl/-vinyl/-1-/methoxy-carbonyl-methyl/- -azetidin-2-one with it's salt with di-p-toluoyl-tartaric acid
US20060293530A1 (en) Process for the manufacture of citalopram hydrobromide
HK1068627B (en) Process for the preparation of racemic citalopram and/or s-or r-citalopram by separation of a mixture of r- and s-citalopram
HK1132729B (en) Process for the preparation of racemic citalopram and/or s- or r-citalopram
HK1071358A1 (en) Process for the preparation of 5-formylphthalide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20081016

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091103